Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2024 | HMAs for MDS- a party of one

In this interview, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses a talk at the ESH MDS 2024 meeting, which focused on hypomethylating agents (HMAs) for the treatment of myelodysplastic syndromes (MDS). To date, combination therapies of HMAs and other agents have failed in Phase III testing; therefore, current treatment approaches utilize single-agent HMA. Prof. Garcia-Manero and the community eagerly await the results of the VERONA trial (NCT04401748), a Phase III trial of venetoclax with azacitidine in treatment-naïve higher-risk (HR) MDS. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.